Benefit Study: Results of Interim Analysis of a Pan-European Observational Study to Evaluate Real-World Effectiveness of SB4 Following Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (AxSpA)

被引：0

作者：

Krueger, Klaus ^{[1
]}

Selmi, Carlo ^{[2
,3
]}

Cantagrel, Alain ^{[4
]}

Abad, Miguel A. ^{[5
]}

Freudensprung, Ulrich ^{[6
]}

Rezk, Mourad Farouk ^{[6
]}

Addison, Janet ^{[7
]}

机构：

[1] Med Ctr Rheumatol, Munich, Germany

[2] Humanitas Res Hosp, Rheumatol & Clin Immunol Unit, Rozzano, MI, Italy

[3] Univ Milan, B1OMETRA Dept, Milan, Italy

[4] CHU, Ctr Rheumatol, Toulouse, France

[5] Hosp Virgen Puerto, FEA Reumatol, Caceres, Spain

[6] Biogen Int GmbH, Zug, Switzerland

[7] Biogen Idec Inc, Maidenhead, Berks, England

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2537

引用

页数：2